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Abstract 
After decades long absence of an official consensus on the most appropriate evaluation 
method for in vitro skin performance of topical semisolid drugs, United States Pharma-
copoeia (USP 39) finally suggested three types of testing equipment; however, all these
provide data on drug release using inert synthetic membranes. Considering the need for a
readily available membrane that would be more structurally similar to human skin, this
paper provides a detailed protocol of a method for drug permeation assessment that uses
heat-separated porcine ear epidermis and modified Franz diffusion cells. Phases that were
shown to be critical for variability of the results are identified (e.g., membrane prepar-
ation), and process parameters optimized. Applicability of the method was tested on four
cream samples loaded with aceclofenac as a model drug. Sample compositions were
designed in such a way to provide „large“ variations (variation of the main stabilizer:
natural-origin versus synthetic emulsifier) and relatively „minor“ variations (co-solvent 
variation: none/isopropanol/glycerol). The developed protocol is a straightforward and
reliable in vitro test for the evaluation of rate and extent of drug delivery into/through the
skin. Moreover, this protocol may be routinely applied even in averagely equipped lab-
oratories during formulation development or preliminary bioequivalence assessment of
generic topical semisolids. 
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The number of generic topical semisolid drugs on 
the world market is somewhat limited, mainly due to 
problems related to establishing bioequivalence with a 
suitable reference [1]. Since the target site of action for 
the majority of topical drugs is the skin itself or subcut-
aneous tissue, establishing bioequivalence usually 
assumes the need for clinical trials, which are asso-
ciated with significant result variability and poor sen-
sitivity in discerning potential differences among similar 
formulations [1–4]. Therefore, in order to facilitate dev-
elopment of high-quality generic topical semisolid 
drugs, regulatory agencies, specifically FDA (Food and 
Drug Administration) and EMA (European Medicines 
Agency), show interest in development of alternative 
approaches [5,6]. Namely, after comparative analysis of 
physical, chemical and microstructure-related critical 
quality attributes of the test and reference preparat-
ions, evaluation of bioequivalence may be performed 
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using a combination of different in vitro and in vivo 
pharmacokinetics-based methods. 
The onset, intensity and duration of a therapeutic 
response after dermal application of semisolid dosage 
forms depend on the relative efficacy of several suc-
cessive processes: drug release from the carrier/base, 
drug penetration into and diffusion across the stratum 
corneum as the rate-limiting skin layer, and subsequent 
drug permeation through viable epidermis and/or der-
mis to the drug-specific receptor [2]. Therefore, in 
order to rationalize both time and funds available for 
formulation development of topical drugs, prior to 
embarking upon time-consuming and expensive in vivo 
studies, in vitro tests are usually performed [7]. While 
the European Pharmacopoeia (Ph. Eur. 9.0) does not 
elaborate on in vitro methods for drug release testing 
from semisolid dosage forms [8], US Pharmacopoeia 
(USP 39) provides a detailed description of three applic-
able methods (vertical diffusion, immersion and flow-
through cells) coupled with inert, porous, synthetic 
membranes [9]. Although we agree that synthetic 
membranes may be reliable enough to provide time-
dependent drug release/liberation profiles, the con-
clusions drawn from such data often cannot relate to 
the actual in vivo performance. This is usually due to 
the inability of synthetic membranes to simulate a 
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complex interplay that occurs between the skin and the 
formulation excipients upon application [10]. There-
fore, we strived to define a detailed protocol of an in 
vitro evaluation approach for drug permeation assess-
ment from topical semisolid preparations involving ver-
tical (Franz) diffusion cells, and a membrane that would 
be more structurally similar to human skin.  
Although isolated human skin is considered a „gold 
standard“, sufficient quantities are generally hard to 
obtain for both ethical and financial reasons (e.g., after 
aesthetic surgery) [1,11,12]. Survey of the available 
literature revealed that similar methods were already 
used for testing (trans)dermal drug delivery of different 
model drugs, and utilize membranes of various origin 
and complexity (skin isolated from different animal 
species, reconstructed human skin equivalents, etc.) 
[11,13–15]. For that reason, Organisation for Economic 
Co-operation and Development (OECD) published a 
guideline stating the suitability of porcine ear skin for 
percutaneous absorption studies, due to the demon-
strated structural, morphological and permeability sim-
ilarities to the human skin [16–18]. Apart from that, 
recent findings even confirmed certain immunological 
similarities of porcine and human skin [19]. 
However, in spite of the numerous efforts in defin-
ing guidelines for in vitro percutaneous absorption test-
ing, studies conducted so far imply that the obtained 
results may be influenced by a number of factors 
[16,20,21]. Therefore, each and every laboratory was 
left to define more precise experimental conditions for 
performing such studies. Additionally, papers in the 
field failed to disclose a detailed methodology or, in our 
opinion, misinterpreted some critical protocol paramet-
ers, leading to results that could not be easily repro-
duced. 
For that reason, the aim of our work was to define a 
detailed protocol for an in vitro drug permeation study 
through heat-separated porcine ear skin epidermis 
using Franz diffusion cells that could be routinely used 
in laboratory settings. Implementation of such a pro-
tocol should enable direct comparison of both rate and 
extent of drug delivery into/through the skin from the 
investigated formulations. Special emphasis was given 
to the optimization of the membrane preparation pro-
tocol, since pig ears are relatively available biological 
materials that could be modelled into an alternative 
membrane for this type of studies. 
EXPERIMENTAL  
Existing publications on in vitro drug permeation 
studies that rely on alternative membranes, suggest 
rather complicated and time-consuming protocols that 
are often lacking data relating to optimal conditions for 
preparation of such membranes [4,22–25]. We opted 
for heat-separated porcine ear epidermis as a suitable 
membrane for this type of experiments, considering 
that drugs enter systemic circulation in superficial der-
mal layers. Consequently, the presence of the entire 
hydrophilic dermis in in vitro settings would serve as an 
artificial barrier for poorly soluble drugs. Therefore, iso-
lated epidermis obtained by a suitable method should 
be a promising model for in vitro drug permeation 
testing [4,20]. 
Our study was divided into three main phases: i) 
optimization of the protocol for heat-separated porcine 
ear epidermis preparation, ii) assessing compatibility of 
the prepared membrane with the modified Franz dif-
fusion cells system, and iii) quantification and calcul-
ation of thus obtained permeation data. The protocol 
was tested for hydrophilic creams as the most fre-
quently used topical semisolid dosage forms.  
Sample design with the purpose of protocol 
applicability assessment 
Tested creams were either stabilized with a sugar 
(i.e., natural-origin) emulsifier of the alkyl polyglucoside 
type (cetearyl glucoside and cetearyl alcohol, SepineoTM 
SE 68, Seppic, France; samples labelled APG), or per-
tained synthetic non-ionic emulsifiers (polysorbate 60 
and cetearyl alcohol, Sigma Aldrich). Such a variation of 
the main emulsion system stabilizer significantly affects 
the cream microstructure, and was regarded as a 
„large“ variation during the method optimization. It 
should be noted that the formulation stabilized with 
synthetic emulsifiers was in fact a pharmacopoeial 
quality non-ionic hydrophilic cream [26], that is often 
used as a reference sample (thus labelled R) [27–30]. 
Additionally, protocol sensitivity to discern „minor“ dif-
ferences in the investigated formulations composition 
was tested with samples based on the aforementioned 
natural-origin emulsifier that were varied in presence 
or absence of certain co-solvents and potential penet-
ration enhancers. This variation was designed at three 
levels (i.e., no co-solvent added (sample APG), addition 
of isopropanol (sample APG+Ipa) or glycerol (sample 
APG+Gly)). All the samples were loaded with 1 mass% 
of aceclofenac as a model drug. 
Membrane (heat-separated porcine ear epidermis) 
preparation 
This experimental phase involved the following 
equipment: ears of domestic white pigs approximately 
4 months old, 0.9 mass% sodium chloride solution, 
scalpel, electrical trimmer HC 5410/15 (Philips, Nether-
lands), tweezers, an in-house made spherical cutter 
(alternatively surgical scissors), phosphate buffer pH 
7.4 (2.38 g Na2HPO4⋅12H2O, 0.19 g KH2PO4, 8.0 g NaCl in 
1 L of highly-purified water), magnetic stirrer with a 
heating function (IKA RH basic 2, IKA, Germany), cotton 
pads and disposable latex gloves. 
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In vitro permeation study using Franz diffusion cells 
and heat-separated porcine ear epidermis 
The second experimental stage required the follow-
ing equipment: modified Franz diffusion cells with a 
surface of 2.01 cm2 available for diffusion and 12 mL 
volume of the receptor compartment (Gauer Glas, Ger-
many), metal clamps N°28 INOX 18/8 that pinch flat 
joints of donor and receptor compartments, Glisseal® 
HV (Borer Chemie, Switzerland) for sealing the joints of 
two cell compartments, ultrasonic bath (Sonorex 
RK102H, Bandelin, Germany), phosphate buffer pH 7.4 
(composition given in section 2.2.), Parafilm® “M” 
(Bemis, USA), balance (Sartorius, Germany), tweezers 
with flattened shovels, 1 mL syringe with 21Gx43/4" 
(0.8 mm×120 mm) needle, investigated samples (acec-
lofenac 1 mass% loaded hydrophilic creams differing in 
base composition). 
Quantification and calculation of drug permeation 
profiles 
Precise quantification of aceclofenac in the sampled 
aliquots is usually conducted using a suitable HPLC 
method that may be coupled with different detectors. 
In our case, an UHPLC–MS/MS method was used as 
described in elsewhere [30]. Since the protocol includes 
a biological material (the membrane), the method 
validation was carried out according to FDA’s guideline 
for bioanalytical methods [31]. 
RESULTS AND DISCUSSION  
After varying multiple parameters such as porcine 
skin cleaning, storage and defrosting conditions (tem-
perature, duration), the following protocol for porcine 
ear-based membrane preparation was defined.  
In order to preserve the skin barrier integrity, ears 
should be taken immediately after slaughtering and 
washed carefully under cold tap water. The skin of the 
outer side of porcine auricle is then carefully separated 
from cartilage by a scalpel. Thus obtained full thickness 
skin is cleaned by cotton pads impregnated with iso-
tonic sodium chloride solution, dried using a cotton 
cloth, protected with an aluminium foil and stored at 
–20 °C, but not longer than a month. During the dev-
elopment of the protocol, transepidermal water loss 
(TEWL) of porcine ear skin was frequently monitored by 
a Tewameter® TM210 (Courage+Khazaka, Germany). 
The obtained values of this biophysical parameter 
showed that the aforementioned temperature and dur-
ation of storage do not affect the skin barrier integrity. 
On the day of the experiment, after defrosting at room 
temperature (22±2 °C, TEWL values are in the range of 
10–20 g m–2 h–1), the hair is carefully cut to 0.5 mm 
length by using an electrical trimmer, and the skin is cut 
in round pieces of 25 mm diameter. Skin cutting may 
be performed by common surgical scissors; alternat-
ively, a custom-made cutter with a spherical blade may 
be used (Figure 1c), since it facilitates this stage and 
provides uniform size. The skin is then immersed in 
purified water heated to 60 °C for 90 s after which the 
epidermis is carefully removed from the dermis by 
tweezers. Isolated epidermis is inspected for physical 
damage with a magnifying glass, transferred to a Petri 
dish with phosphate buffer pH 7.4 and left to hydrate 
for 1 h. 
After successful membrane preparation, its suitab-
ility for application in modified Franz diffusion cell 
setup was assessed. Firstly, the joints of donor and 
receptor compartments of diffusion cells are sealed 
using a small amount of Glisseal® HV in order to pre-
vent water entry into the cell during the experiment. A 
stirring magnet is placed in each receptor compartment 
that is subsequently completely filled with phosphate 
buffer pH 7.4 that was previously submitted to sonic-
ation for 30 min (for the sake of air bubbles removal) 
and heated to 32 °C (average skin surface tempera-
ture). Porcine ear epidermis is then placed with utmost 
care between the donor and receptor compartments 
(stratum corneum facing the donor part) using a flat-
tened shovels tweezer, and the compartments are fixed 
by a clamp. Receptor parts of the cells are immersed 
into a water bath at 32 °C in order to equilibrate the 
 
Figure 1. Schematic representation of the protocol for the preparation of heat-separated porcine ear epidermis that precedes the 
actual drug permeation assessment: a) the photograph of a porcine ear, as received after slaughtering, b) the photograph of the 
outer side of porcine auricle skin when separated from cartilage, c) the use of the spherical cutter ensures uniform membrane 
dimensions, d) the photograph of the isolated epidermis placed in a Petri dish versus a full thickness skin membrane, and e) 
the final setup of the modified Franz diffusion cells. 
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membranes under constant magnet stirring at 500 rpm. 
After 30 min, 1 g of each sample is weighted and uni-
formly applied to the membrane surface. The donor 
compartment is then occluded using Parafilm®. Drug 
permeation through the heat-separated porcine ear 
epidermis is investigated over the next 30 h to achieve 
the steady-state as well as to avoid inevitable degrad-
ation of the skin barrier. The temperature and stirring 
speed are kept constant. At previously defined time 
points (in our case: 2, 4, 6, 8, 20, 22, 24, 26, 28 and 30 
h), 600 μL aliquots are sampled by a needle and syringe 
with special care to prevent air bubbles formation. 
After each sampling, the system is refilled with an 
equal volume of heated, degassed phosphate buffer, in 
order to maintain sink conditions. Aceclofenac concen-
tration in sampled aliquots is then determined by an 
appropriate UHPLC–MS/MS method. 
Output of such analytical methods is usually pre-
sented as drug concentration (e.g., μg of aceclofenac 
per mL) and need to be further corrected for the sake 
of proper results discussion. The stepwise calculation 
leading to the actual drug permeation profile is dis-
closed henceforth. 
The obtained drug concentrations are first cor-
rected to the buffer volume in receptor compartments 
(12 mL) and aliquot volume sampled in predefined time 
points (600 µL), and then divided with the surface avail-
able for diffusion (2.01 cm2), in order to finally be exp-
ressed as cumulative amounts of drug permeated per 
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where Q1, Q2, Q3, etc., represent aceclofenac amount 
that permeated per membrane (heat-separated epider-
mis) surface unit at times t1, t2, t3, etc.; C1, C2, C3, etc. – 
drug concentrations (μg of aceclofenac per mL) in ali-
quots sampled at appropriate time points (t1, t2, t3, 
etc.), determined via UHPLC–MS/MS method; VC – vol-
ume of the diffusion cell receptor compartment; VU – 
volume of the phosphate buffer sampled at times t1, t2, 
t3, etc.; and P – surface of the diffusion cell available for 
drug diffusion. 
For better clarity, the obtained results may be fur-
ther graphically presented as time (ti) dependent plots 
of the cumulative drug amount (Qi) that permeates 
through the surface unit of heat-separated porcine ear 
epidermis (Figure 2). The obtained permeation profiles 
enable direct comparison of drug (aceclofenac) delivery 
efficacy into/through the skin from various formulations. 
In order to fully characterize drug permeation pro-
cess through heat-separated porcine ear epidermis 
from the selected formulations, besides permeation 
profiles, values of the following parameters are also 
calculated: total amount of drug permeated through 
the membrane at the end of the experiment (Q30h), 
steady-state flux (Jss) and permeability coefficient (Kp). 
Steady-state flux (Jss) of the drug through the skin is 
determined from the linear portion of the slope of the 
cumulative amount of the drug that permeates through 
the membrane surface unit versus time plot, for each 
investigated formulation and each used diffusion cell. 
Linear portion of the curve is obtained using linear reg-
ression analysis of a sufficient number of measuring 
points in the steady-state phase. After this, perme-
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Figure 2. Comparative representation of aceclofenac permeation profiles from the investigated samples: a) comparison of samples 
with „large“ variations in delivery system microstructure and b) comparison of samples with „minor“ variations in formulation 
composition (mean values ± standard deviations, n = 6).
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where Jss is the steady-state flux of the drug through 
the skin (µg/(cm2 h)), and Co initial drug (aceclofenac) 
concentration in the tested formulation (µg/mg). 
Aceclofenac permeation profiles shown in Figure 2, 
as well as the values of steady-state flux, permeation 
coefficient and the total amount of aceclofenac that 
permeated through the skin at the end of the expe-
riment imply that the presented protocol is successful 
in discerning differences in aceclofenac availability 
from the investigated hydrophilic creams. As expected, 
the protocol was able to point towards the differences 
in aceclofenac permeation parameters from APG vs. R 
samples. In fact, the difference in the two samples’ 
microstructure has resulted in a nearly two-fold higher 
Jss, Q30h and Kp values (p < 0.05) in favour of the aceclo-
fenac sample stabilized with the natural-origin emul-
sifier (calculated values for sample APG were 1.22±  
±0.19 µg/(cm2 h), 21.04±2.04 µg/cm2 and 0.12±0.02 
mg/(cm2 h), respectively; while the corresponding 
values for sample R were 0.57±0.09 µg/(cm2 h), 
12.62±1.88 µg/cm2 and 0.06±0.01 mg/(cm2 h)). Admit-
tedly, such substantial formulation variations (i.e., 
„large“ variations) could also be revealed via in vitro 
release tests equipped with synthetic membranes, such 
as polycarbonate ones our group has used in reference 
[30]. Naturally, the differences of the aforementioned 
permeation parameters among the samples that end-
ured smaller composition variations (i.e., co-solvent 
addition) were not as prominent but were still notable 
(Jss was found to be 1.6-fold; Q30h 1.8-fold and Kp 1.5- 
-fold higher for the sample APG+Ipa as compared to 
the sample APG+Gly). In fact, the sample APG+Ipa pro-
vided a significant increase in aceclofenac permeation 
rate, Q30h and permeation coefficient (1.50±0.08 µg/ 
/(cm2 h), 34.36±2.97 µg/cm2 and 0.15±0.01 mg/(cm2 h), 
respectively), all p < 0.05 when compared to other 
three tested samples. Contrary to these findings, when 
synthetic membranes are used instead of heat-separ-
ated porcine ear epidermis, the impact of isopropyl 
alcohol as a permeation enhancer with multifaceted 
mechanism of skin interactions [32], could not be det-
ected. In fact, aceclofenac release testing through poly-
carbonate membranes favoured the basic APG sample, 
and not APG+Ipa sample (release rate and extent attri-
buted to the sample APG were significantly higher 
when compared to all other tested samples; p < 0.05) 
[30]. This is another obvious contribution of bio-deri-
ved membranes application in elucidation of slight dif-
ferences in the assessed topical semisolids. 
The obtained results suggest that the defined pro-
tocol is able to detect the influence of relatively small 
variations in formulation of topical semisolids on der-
mal availability of the incorporated drug. Namely, 
although the composition of the tested alkyl polygluco-
side-based creams differ only in the addition of a co- 
-solvent (basic sample without a co-solvent (APG), 
sample with isopropanol (APG+Ipa) and sample with 
glycerol (APG+Gly)), clear differences in the recorded 
rate and extent of aceclofenac permeation could be 
discerned when heat-separated porcine ear epidermis 
was used as a membrane. Additionally, the results 
obtained by using this method are satisfactorily cor-
related to in vivo data obtained by a tape stripping 
method on human volunteers (R2 = 0.9802; data not 
shown), which asserts the suitability of the method in 
detection of potential differences among formulations 
of the same dosage form [30]. Therefore, the data 
obtained by the presented in vitro method could also 
contribute to rationalization of consecutive assessment 
of product bioequivalence. 
CONCLUSIONS  
A protocol envisioned for in vitro efficacy assess-
ment of topical semisolid drugs is presented in detail. 
The added value of such a permeation study lies in the 
application of a membrane (heat-separated porcine ear 
epidermis) that is relatively easily obtained and struc-
turally similar to the human skin. Applicability of the 
protocol was shown for: i) aceclofenac permeation 
study from hydrophilic creams of relatively simple com-
position stabilized with a natural-origin alkyl polyglu-
coside emulsifier vs. a reference pharmacopoeial cream 
stabilized with a synthetic non-ionic emulsifier; ii) direct 
comparison of rate and extent of aceclofenac perme-
ation from the alkyl polyglucoside-based samples vary-
ing in addition of co-solvents/potential penetration 
enhancers (isopropanol, glycerol). 
The presented protocol does not require expensive 
state-of-the-art equipment but rather relies on tools 
that may be found in every research laboratory focused 
on topical preparations. It is our opinion that 
researchers could benefit from such a protocol espe-
cially during formulation development, when selection 
should be made among a large number of formulation-
candidates. This assumes that various formulations of 
the same dosage form (e.g., creams, ointments or gels) 
could be submitted to a comparative assessment in 
order to reveal the most promising formulation regard-
ing the expected relative bioavailability of the incur-
porated drug. Such a method could even serve for pre-
liminary assessment of bioequivalence with generic 
topical semisolid drugs of the same dosage form. 
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(Stručni rad) 
Nakon dugogodišnjeg nepostojanja zvaničnog stava o preporučenim meto-
dama in vitro ispitivanja lekova polučvrste konzistencije za primenu na koži,
Američka farmakopeja (USP 39) navodi vertikalnu difuzionu, imerzionu i protočnu
ćeliju, kao tri vrste uređaja za ispitivanje. Iako sve navedene metode pružaju uvid
u brzinu oslobađanja lekovite supstance iz ispitivanog preparata, one podrazu-
mevaju upotrebu inertnih sintetskih membrana koje u dovoljnoj meri ne simu-
liraju kompleksnu strukturu kože i interakciju sa primenjenim preparatom. Imajući
u vidu potrebu za lako dostupnom membranom koja bi po svojim karakteris-
tikama bila sličnija humanoj koži, ovaj rad predlaže detaljan protokol metode za
procenu permeacije lekova primenom epidermisa uha svinje izolovanog toplotom 
i modifikovane Francove difuzione ćelije. U radu su prepoznate kritične faze nave-
dene metode (npr. priprema membrane), čijom se optimizacijom procesnih 
parametara smanjuje varijabilnost dobijenih rezultata. Osetljivost metode ispitana
je na četiri jednostavna preparata tipa hidrofilnog krema sa aceklofenakom kao 
model lekovitom supstancom. Sastav preparata je koncipiran tako da obezbedi
„velike“ razlike (npr. variranje osnovnog stabilizatora: emulgator prirodnog versus
sintetskog porekla), kao i „male“ razlike u mikrostrukturi (npr. variranje koras-
tvarača: bez korastvarača/izopropanol/glicerol), a sa ciljem njihove detekcije
primenom razvijenog protokola. Razvijen protokol predstavlja jednostavnu i 
pouzdanu in vitro metodu za procenu brzine i obima isporuke lekovite supstance 
u/kroz kožu iz polučvrstih preparata. Ova metoda se može primeniti prilikom
poređenja različitih formulacija u fazama razvoja novog leka ili preliminarne pro-
cene biološke ekvivalentosti generičkih preparata, čak i u laboratorijama prosečne
opremljenosti. 
  Ključne reči: Dermalna isporuka lekovite 
supstance • Brzina i stepen permeacije 
leka • Hidrofilni kremovi • Aceklofenak 
 
